Jan 29 (Reuters) - Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.7 USD | -0.09% | -2.47% | +36.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.58% | 12.46B | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+288.77% | 8.12B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta says its experimental Duchenne drug more effective than older medicine